Literature DB >> 25336551

Add-on oral olanzapine worsens hallucinations in schizoaffective disorder.

Umberto Volpe1, Annarita Vignapiano1, Olimpia Gallo1, Michele Fabrazzo1.   

Abstract

Anecdotal evidence tends to favour olanzapine in the treatment of hallucinations in patients with schizophrenia spectrum disorders; however, no conclusive evidence is available on this topic. We report here a clinical case in which a 46-year-old man, suffering from a schizoaffective disorder (depressed type), underwent olanzapine treatment (20 mg/day). After inducing an initial amelioration, the patient had a re-exacerbation of auditory hallucinations and a clinical and psychosocial worsening, which subsided after olanzapine discontinuation. Olanzapine may induce a worsening of hallucinations in a psychotic disorder with substantial affective component and therefore its use should be carefully evaluated in such cases. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25336551      PMCID: PMC4208114          DOI: 10.1136/bcr-2014-205805

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  19 in total

1.  Valproate lowers plasma concentration of olanzapine.

Authors:  Niels Bergemann; Kai R Kress; Fatima Abu-Tair; Alex Frick; Jürgen Kopitz
Journal:  J Clin Psychopharmacol       Date:  2006-08       Impact factor: 3.153

2.  Proposal for a new tool to evaluate drug interaction cases.

Authors:  John R Horn; Philip D Hansten; Lingtak-Neander Chan
Journal:  Ann Pharmacother       Date:  2007-03-27       Impact factor: 3.154

3.  Valproic Acid significantly lowers serum concentrations of olanzapine-an interaction effect comparable with smoking.

Authors:  Tore Haslemo; Kristine Olsen; Hilde Lunde; Espen Molden
Journal:  Ther Drug Monit       Date:  2012-10       Impact factor: 3.681

Review 4.  Olanzapine versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Heike Hunger; Franziska Schmid; Sandra Schwarz; Lorna Duggan; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

5.  Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder.

Authors:  Edoardo Spina; Concetta D'Arrigo; Vincenza Santoro; Maria Rosaria Muscatello; Gianluca Pandolfo; Rocco Zoccali; Francisco J Diaz; Jose de Leon
Journal:  Ther Drug Monit       Date:  2009-12       Impact factor: 3.681

6.  Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication.

Authors:  Marianne Gex-Fabry; Androniki E Balant-Gorgia; Luc P Balant
Journal:  Ther Drug Monit       Date:  2003-02       Impact factor: 3.681

7.  An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses.

Authors:  John D Matthews; Kathryn A Bottonari; Laura M Polania; David Mischoulon; Christina M Dording; Robert Irvin; Maurizio Fava
Journal:  J Clin Psychiatry       Date:  2002-12       Impact factor: 4.384

Review 8.  Second-generation antipsychotics for schizophrenia: can we resolve the conflict?

Authors:  S Leucht; W Kissling; J M Davis
Journal:  Psychol Med       Date:  2009-04-01       Impact factor: 7.723

9.  Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients.

Authors:  N Bergemann; A Frick; P Parzer; J Kopitz
Journal:  Pharmacopsychiatry       Date:  2004-03       Impact factor: 5.788

10.  Is schizoaffective disorder a distinct categorical diagnosis? A critical review of the literature.

Authors:  Daniel J Abrams; Donald C Rojas; David B Arciniegas
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.